Trial Profile
A GOIRC Phase II randomized trial of an oral chemotherapy combination of Capecitabine plus Vinorelbine and their sequential single agent use in Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms GOIRC
- 16 Jun 2011 New trial record